Filtered By:
Infectious Disease: COVID-19
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery
J Control Release. 2022 Nov 10:S0168-3659(22)00739-8. doi: 10.1016/j.jconrel.2022.10.061. Online ahead of print.ABSTRACTWith the rapid development of biopharmaceuticals and the outbreak of COVID-19, the world has ushered in a frenzy to develop gene therapy. Therefore, therapeutic genes have received enormous attention. However, due to the extreme instability and low intracellular gene expression of naked genes, specific vectors are required. Viral vectors are widely used attributed to their high transfection efficiency. However, due to the safety concerns of viral vectors, nanotechnology-based non-viral vectors have attrac...
Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Hezhi Wang Lu Qin Xin Zhang Jian Guan Shirui Mao Source Type: research
Directing the Way-Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Pharm Res. 2022 Sep 15. doi: 10.1007/s11095-022-03385-w. Online ahead of print.ABSTRACTNucleic acid therapeutics have shown great potential for the treatment of numerous diseases, such as genetic disorders, cancer and infections. Moreover, they have been successfully used as vaccines during the COVID-19 pandemic. In order to unfold full therapeutical potential, these nano agents have to overcome several barriers. Therefore, directed transport to specific tissues and cell types remains a central challenge to receive carrier systems with enhanced efficiency and desired biodistribution profiles. Active targeting strategies in...
Source: Cell Research - September 15, 2022 Category: Cytology Authors: Ricarda Carolin Steffens Ernst Wagner Source Type: research
Directing the Way —Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
AbstractNucleic acid therapeutics have shown great potential for the treatment of numerous diseases, such as genetic disorders, cancer and infections. Moreover, they have been successfully used as vaccines during the COVID-19 pandemic. In order to unfold full therapeutical potential, these nano agents have to overcome several barriers. Therefore, directed transport to specific tissues and cell types remains a central challenge to receive carrier systems with enhanced efficiency and desired biodistribution profiles. Active targeting strategies include receptor-targeting, mediating cellular uptake based on ligand-receptor in...
Source: Pharmaceutical Research - September 15, 2022 Category: Drugs & Pharmacology Source Type: research
A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
J Control Release. 2022 Aug 10:S0168-3659(22)00514-4. doi: 10.1016/j.jconrel.2022.08.009. Online ahead of print.ABSTRACTSince the recent clinical approval of siRNA-based drugs and COVID-19 mRNA vaccines, the potential of RNA therapeutics for patient healthcare has become widely accepted. Lipid nanoparticles (LNPs) are currently the most advanced nanocarriers for RNA packaging and delivery. Nevertheless, the intracellular delivery efficiency of state-of-the-art LNPs remains relatively low and safety- and immunogenicity concerns with synthetic lipid components persist, altogether rationalizing the exploration of alternative ...
Source: Cancer Control - August 13, 2022 Category: Cancer & Oncology Authors: Bram Bogaert F élix Sauvage Roberta Guagliardo Cristina Muntean Van Phuc Nguyen Eline Pottie Mike Wels An-Katrien Minnaert Riet De Rycke Qiangbing Yang Dan Peer Niek Sanders Katrien Remaut Yannis M Paulus Christophe Stove Stefaan C De Smedt Koen Raemdonc Source Type: research
Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research
